Therapeutic pipeline for soft-tissue sarcoma

Bibliography

• Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005;12:701-11
   Google Scholar
• Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685-94
   PubMed Web of Science ®Google Scholar
• Italiano A, Mathoulin-Pelissier S, Cesne AL, Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 2011;117(5):1049-54
   PubMed Web of Science ®Google Scholar
• Ducimetiere F, Lurkin A, Ranchere-Vince D, Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhone-Alpes region. Bull Cancer 2010;97:629-41
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10
   PubMed Web of Science ®Google Scholar
• Cassier PA, Blay JY. Imatinib mesylate for the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther 2010;10:623-34
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD, Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32
   PubMed Web of Science ®Google Scholar
• Reichardt P, Blay J, Gelderblom H, Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. J Clin Oncol 2010;28:10017
   Google Scholar
• Heinrich MC, Wise S, Hood M, In vitro activity of novel KIT/PDGFRA switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors. J Clin Oncol 2010;28:10007
   Web of Science ®Google Scholar
• George S, Von Mehren M, Heinrich MC, A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol 2011;29:10007
   Google Scholar
• Available from: www.clinicaltrials.gov 2011
   Google Scholar
• Tarn C, Skorobogatko YV, Taguchi T, Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006;66:5477-86
   PubMed Web of Science ®Google Scholar
• Schoffski P, Reichardt P, Blay JY, A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 2010;21(10):1990-8
   Google Scholar
• Bendell JC, Wagner AJ, Dolly S, A first in human phase I study to evaluated the dual PI3K/mTOR inhibitor GDC-0980 administered qd in patients with advanced solid tumors or non hodgkin's lymphoma (NHL). 35th ESMO meeting Abstracts 21[Suppl 8]. 8-10-2010
   Google Scholar
• Baird RD, Kristeleit RS, Sarker D, A Phase I Study Evaluating the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the oral Pan-Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941. 35th ESMO meeting Abstracts 21[Suppl 8]. 8-10-2010
   Google Scholar
• Rutkowski P, Van Glabbeke M, Rankin CJ, Imatinib Mesylate in advanced Dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010;28:1772-9
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Maki RG, Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 2009;27:3148-53
   PubMed Web of Science ®Google Scholar
• D'Adamo DR, Anderson SE, Albritton K, Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-42
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Quinn R. Rabinowitz I, rias-Pulido H, Muller C. Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS). J Clin Oncol 2008;26:10534
   Google Scholar
• George S, Merriam P, Maki RG, Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154-60
   PubMed Web of Science ®Google Scholar
• Mahmood ST, Agresta S, Vigil C, Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma. Int J Cancer 2010. 2010 Dec 10. [Epub ahead of print]
   Web of Science ®Google Scholar
• Maki RG, D'Adamo DR, Keohan ML, Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133-40
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-32
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal endpoint for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-9
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay J, Chawla SP, PALETTE: a randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy–An EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 2011;29:LBA10002
   Google Scholar
• Ratain MJ, Schwartz GK, Oza AM, Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2011;29:3079
   Web of Science ®Google Scholar
• Schwartz GK, Maki RG, Ratain MJ, Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. J Clin Oncol 2011;29:10000
   Web of Science ®Google Scholar
• Christopherson WM, Foote FW Jr, Stewart FW. Alveolar soft-part sarcomas; structurally characteristic tumors of uncertain histogenesis. Cancer 1952;5:100-11
   PubMed Web of Science ®Google Scholar
• Azizi AA, Haberler C, Czech T, Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol 2006;7:521-3
   PubMed Web of Science ®Google Scholar
• Lazar AJ, Das P, Tuvin D, Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 2007;13:7314-21
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Tamborini E, Marrari A, Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009;15(3):1096-104
   PubMedGoogle Scholar
• Gardner K, Judson I, Leahy M, Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol 2009;27:10523
   Google Scholar
• Bay J, Le Cesne A, Cioffi A, A national registry for the off-label use of targeted therapies in patients (pts) with malignant mesenchymal tumors: A retrospective study from the GSF-GETO. J Clin Oncol 2010;28:10097
   Google Scholar
• Kummar S, Strassberger A, Monks A, An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). J Clin Oncol 2011;29:10001
   Google Scholar
• Fayette J, Martin E, Piperno-Neumann S, Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007;18:2030-6
   PubMed Web of Science ®Google Scholar
• Penel N, Ray-Coquard I, Cioffi A, A stratified phase II trial investigating sorafenib (SORA) in patients (pts) with metastatic or locally advanced angiosarcoma (AS). J Clin Oncol 2010;28:10026
   Google Scholar
• Penel N, Bui BN, Bay JO, Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008;26:5269-74
   PubMed Web of Science ®Google Scholar
• Agulnik M, Okuno SH, Von Mehren M, An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. J Clin Oncol 2009;27:10522
   Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35
   PubMed Web of Science ®Google Scholar
• Hernando E, Charytonowicz E, Dudas ME, The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007;13:748-53
   PubMed Web of Science ®Google Scholar
• Tomita Y, Morooka T, Hoshida Y, Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 2006;12:3070-7
   PubMed Web of Science ®Google Scholar
• Zhu QS, Ren W, Korchin B, Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res 2008;68:2895-903
   PubMed Web of Science ®Google Scholar
• Okuno S, Bailey H, Mahoney MR, A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the mayo phase 2 consortium (P2C). Cancer 2011;117(15):3468-75
   PubMedGoogle Scholar
• Chawla SP, Tolcher AW, Staddon AP, Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J Clin Oncol 2006;24:9505
   Google Scholar
• Ganjoo K, Jacobs C. Antiangiogenesis agents in the treatment of soft tissue sarcomas. Cancer 2010;116:1177-83
   PubMedGoogle Scholar
• Chawla SP, Blay J, Ray-Coquard IL, Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 2011;29:10005
   Web of Science ®Google Scholar
• Schuetze S, Zhao L, Chugh R, Results of a phase II trial of sirolimus (S) and cyclophosphamide (C) in advanced sarcoma. J Clin Oncol 2011;29:10003
   Web of Science ®Google Scholar
• El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003;361:1348-9
   PubMedGoogle Scholar
• Pan CC, Chung MY, Ng KF, Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. J Pathol 2008;214:387-93
   PubMed Web of Science ®Google Scholar
• Kenerson H, Folpe AL, Takayama TK, Yeung RS. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol 2007;38:1361-71
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010;28:835-40
   PubMed Web of Science ®Google Scholar
• Italiano A, Delcambre C, Hostein I, Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 2010;21:1135-7
   PubMed Web of Science ®Google Scholar
• Subbiah V, Trent JC, Kurzrock R. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol 2010;28:e415
   PubMedGoogle Scholar
• Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010;28:4985-95
   PubMed Web of Science ®Google Scholar
• Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994;54:2803-7
   PubMed Web of Science ®Google Scholar
• Karnieli E, Werner H, Rauscher FJ III, The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein. J Biol Chem 1996;271:19304-9
   PubMedGoogle Scholar
• Toretsky JA, Kalebic T, Blakesley V, The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-7
   PubMed Web of Science ®Google Scholar
• Finkeltov I, Kuhn S, Glaser T, Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein. Oncogene 2002;21:1890-8
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Rothenberg ML, Rodon J, A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007;25:3002
   Google Scholar
• Olmos D, Tan DS, Jones RL, Judson IR. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J 2010;16:183-94
   PubMed Web of Science ®Google Scholar
• Pappo AS, Patel S, Crowley J, Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): results of a phase II SARC study. J Clin Oncol 2010;28:10000
   Google Scholar
• Tap WD, Demetri GD, Barnette P, AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results. J Clin Oncol 2010;28:10001
   Google Scholar
• Schoffski P, Adkins D, Blay J, Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors. J Clin Oncol 2011;29:10004
   Web of Science ®Google Scholar
• Quek R, Wang Q, Morgan JA, Combination mTOR and IGF-1R inhibition: phase I trial of Everolimus and Figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011;17:871-9
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51
   PubMed Web of Science ®Google Scholar
• Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010;16:3526-32
   PubMed Web of Science ®Google Scholar
• Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 2010;456:167-79
   PubMed Web of Science ®Google Scholar
• Italiano A, Bianchini L, Gjernes E, Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 2009;15:5696-703
   PubMedGoogle Scholar
• Ray-Coquard IL, Blay J, Italiano A, Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) biomarker study. J Clin Oncol 2011;29:10007b
   Google Scholar
• Pasca di MM, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 2003;3:903-11
   PubMedGoogle Scholar
• Xie J, Murone M, Luoh SM, Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90-2
   PubMed Web of Science ®Google Scholar
• Dong J, Gailani MR, Pomeroy SL, Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat 2000;16:89-90
   PubMedGoogle Scholar
• Von Hoff DD, LoRusso PM, Rudin CM, Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Laterra J, Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-8
   PubMed Web of Science ®Google Scholar
• Zibat A, Missiaglia E, Rosenberger A, Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene 2010;29:6323-30
   PubMed Web of Science ®Google Scholar
• Hirotsu M, Setoguchi T, Sasaki H, Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer 2010;9:5
   PubMed Web of Science ®Google Scholar
• Tiet TD, Hopyan S, Nadesan P, Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am J Pathol 2006;168:321-30
   PubMedGoogle Scholar
• Joo J, Christensen L, Warner K, GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS One 2009;4:e7608
   Google Scholar
• Beauchamp E, Bulut G, Abaan O, GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 2009;284:9074-82
   PubMed Web of Science ®Google Scholar
• Roma J, Masia A, Reventos J, Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res 2011;17:505-13
   PubMedGoogle Scholar
• Tanaka M, Setoguchi T, Hirotsu M, Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 2009;100:1957-65
   PubMed Web of Science ®Google Scholar
• Ban J, nani-Baiti IM, Kauer M, EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 2008;68:7100-9
   PubMed Web of Science ®Google Scholar
• Butrynski JE, D'Adamo DR, Hornick JL, Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363(18):1727-33
   PubMed Web of Science ®Google Scholar